Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 02, 2020

Use of Immunotherapy With PD-1 vs PD-L1 Inhibitors in Patients With Cancer

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-Analysis
JAMA Oncol 2019 Dec 26;[EPub Ahead of Print], J Duan, L Cui, X Zhao, H Bai, S Cai, G Wang, Z Zhao, J Zhao, S Chen, J Song, C Qi, Q Wang, M Huang, Y Zhang, D Huang, Y Bai, F Sun, JJ Lee, Z Wang, J Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading